The RetInSight GA Monitor for Geographic Atrophy (GA)

Welcome to the future of geographic atrophy management with the RetInSight GA Monitor. Our groundbreaking AI-based technology brings forth a new era in GA segmentation and visualization, making the invisible visible.

Key features of the RetInSight GA Monitor

  • AI-based segmentation: Advanced AI algorithms enable precise segmentation of GA areas
  • Complete disease activity assessment: Measure and visualize disease activity and therapeutic efficacy across all aspects, including photoreceptor (PR) degeneration12, retinal pigment epithelium (RPE) loss consistent with FAF13, and PR/RPE overlap14
  • Enhanced disease monitoring: Visualize and track disease progression, allowing for precise and timely interventions

The RetInSight GA Monitor fulfills all MDR 2017/745 requirements for class IIa medical devices as Clinical Decision Support Systems (CDSS) for the monitoring of patients with GA.

How the RetInSight GA Monitor will benefit your clinical routine

GA Monitor Sample Report

The GA Monitor is specifically designed to empower GA treatment, enabling visualization and quantification of photoreceptor (PR) and retinal pigment epithelium (RPE) loss.

  • Unique photoreceptor measurement: Be at the forefront of GA treatment with our unique ability to measure photoreceptor integrity loss, the very essence of vision. With the help of a specifically trained AI-supported algorithm the level and extent of photoreceptor thinning, referred to as EZ (ellipsoid zone) attenuation, is identified by a cloud-based software.
  • Differentiation of progressors: Identify slow vs. fast progressors at the first presentation, enabling personalized treatment plans and improved patient outcomes.
  • Efficient workflow: Integrate GA management seamlessly into your current optical coherence tomography (OCT) routine, streamlining workflow and enhancing efficiency with just one mouse click.

Empowering GA treatment through visualization and quantification of PR and RPE loss

As a trusted leader in retinal care, RetInSight invites you to explore the GA Monitor and experience the next generation of GA management. Our innovative technology will empower you to make informed treatment decisions based on precise measurements and visualizations of PR and RPE loss, all while remaining committed to preserving your patients’ vision throughout their lifetime.

For more information and details on the GA Monitor, please get in touch with our team. Together, let’s revolutionize the way we manage and treat geographic atrophy.

Contact RetInSight

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

References

  1. Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, Schmidt-Erfurth U. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016 Feb;134(2):182-90. doi: 10.1001/jamaophthalmol.2015.4948. PMID: 26661463.
  2. Gregor S. Reiter et al. Performance of an Artificial Intelligence Decision Support Tool, The Vienna Fluid Monitor in Neovascular Age-Related Macular Degeneration. Presentation at Euretina 2022.
  3. Gerendas, Bianca S. et al. VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS. Retina 42(9):p 1673-1682, September 2022. | DOI: 10.1097/IAE.0000000000003557.
  4. Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye 35, 2983–2990 (2021). https://doi.org/10.1038/s41433-020-01354-4
  5. Ursula Schmidt-Erfurth et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Progress in Retinal and Eye Research. Volume 86, 2022, 100972, ISSN 1350-9462, https://doi.org/10.1016/j.preteyeres.2021.100972.
  6. Chaudhary, Varun et al. IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review. Retina 42(4):p 589-606, April 2022. DOI: 10.1097/IAE.0000000000003283.
  7. Aslam, T.M., Mahmood, S., Balaskas, K. et al. Statistical Modelling of the Visual Impact of Subretinal Fluid and Associated Features. Ophthalmol Ther 10, 127–135 (2021). https://doi.org/10.1007/s40123-020-00327-w
  8. Ursula Schmidt-Erfurth et al. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, Volume 2, Issue 1,2018, Pages 24-30, ISSN 2468-6530. DOI: https://doi.org/10.1016/j.oret.2017.03.015.
  9. Euretina 2021 Clinical Survey Outcomes.
  10. Data on file RetInSight.
  11. Michl M et al. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. Eye (Lond). 2022 Dec 28. doi: 10.1038/s41433-022-02376-w. Epub ahead of print. PMID: 36577804.
  12. Mai, Julia et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. Am J Ophthalmol. 2022 Dec;244:175-182. doi: 10.1016/j.ajo.2022.06.023. Epub 2022 Jul 16.
  13. Riedl, Sophie et al. The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis. Ophthalmol Retina. 2022 Nov;6(11):1009-1018. doi: 10.1016/j.oret.2022.05.030. Epub 2022 Jun 3.
  14. Vogl, Wolf-Dieter et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina. 2023 Jan;7(1):4-13. doi: 10.1016/j.oret.2022.08.003. Epub 2022 Aug 7.

Clinical Decision Support System (CDSS)​

The RetInSight Fluid Monitor is a fully automated comprehensive AI-based Clinical Decision Support System, consisting of:​

  • The artificial intelligence software​
  • The web-based customer portal​
  • The Instruction for Use in the required languages​
  • The secure cloud-based image analysis server​
  • The secured data exchange via internet connection​
  • The cloud-based web service for back-end data storage and maintenance​
  • Compliance with the current EU medical device regulation ​
  • Customer support​

As a CDSS, the RetInSight Fluid Monitor facilitates decision-making in patient management, but it does not provide an autonomous recommendation.​

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

​